

1. FURTHER INFORMATION ABOUT OUR COMPANY**A. Incorporation**

In January 1983, China Isotope Company Limited, our predecessor, was incorporated as a company owned by the whole people in PRC by the Ministry of Nuclear Industry. In December 2007, we underwent a restructuring, and transformed into a limited liability company. In December 2011, our Company was converted to a joint stock company with limited liability.

We have established a place of business in Hong Kong at Level 54, Hopewell Center, 183 Queen's Road East, and has been registered as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance on May 2, 2017. Ms. Kam Mei Ha, Wendy, has been appointed as our agent for the acceptance of service of process and notices on behalf our Company in Hong Kong.

As our Company was established in the PRC, we are subject to the relevant PRC laws and regulations. A summary of the relevant aspects of PRC laws and regulations and a summary of our Articles of Association is set out in Appendices IV and V to this prospectus, respectively.

B. Changes in the Share Capital of Our Company

- In December 2007, our Company was restructured into a limited liability company.
- In May 2008, our registered capital was increased from RMB50,000,000 to RMB60,000,000.
- In June 2009, our registered capital was increased to RMB62,800,000.
- In April 2010, our registered capital was increased to RMB74,000,000.
- In May 2011, CNNC transferred its 26.92% and 21.15% equity interests held in China Isotope Company to the CIAE and the NPIC respectively.
- In December 2011, our Company was converted to a joint stock company with its registered capital increased to RMB200,000,000.
- In March 2017, our registered capital was further increased to RMB239,906,100.

Upon completion of the Global Offering, without taking into account any H Shares which may be issued pursuant to the Over-allotment Option, our registered share capital will be increased to RMB319,874,800, comprising 239,906,100 Domestic Shares and 79,968,700 H Shares issued under the Global Offering, representing approximately 75.00% and 25.00% of our enlarged registered capital, respectively.

Save as disclosed above, there has been no alteration in the share capital of our Company since its establishment.

C. Written Resolutions Passed by Our Shareholders

On March 6, 2017 and March 31, 2017, the Shareholders of our Company passed, among other things, the following resolutions:

- (a) the issue by our Company of H Shares of nominal value of RMB1.00 each up to 79,968,700 H Shares in total (without taking into account the H Shares which may be issued upon the exercise of the Over-allotment Option) and subsequent listing of such H Shares on the Stock Exchange;

- (b) the granting of the Over-allotment Option in respect of no more than 15% of the number of H Shares issued as above-mentioned;
- (c) subject to the completion of the Global Offering, the Articles of Association have been approved and adopted, which shall only become effective from the Listing Date and the Board has been authorized to amend the Articles of Association in accordance with any comments from the Stock Exchange and the relevant PRC regulatory authorities; and
- (d) approving the Board to handle all matters relating to, among other things, the issue of H Shares and the listing of H Shares on the Stock Exchange.

D. Changes in Share Capital of Our Subsidiaries

Our principal subsidiaries (for the purpose of the Listing Rules) as of the date of this prospectus are set out under the financial information in the Accountants' Report as included in Appendix I to this prospectus.

There has been no change in the share capital of any our principal subsidiaries within the two years immediately preceding the date of this prospectus.

2. FURTHER INFORMATION ABOUT OUR BUSINESS

A. Summary of Our Material Contracts

We have entered into the following contracts (not being contracts entered into in the ordinary course of business) within two years preceding the date of this prospectus which are or may be material:

- (a) a non-competition and exclusive sales cooperation agreement in respect of radioactive sources, isotope and irradiation business dated August 1, 2016 entered into between the Company and CIAE, pursuant to which CIAE agreed to, among others, provide certain non-competition undertakings in favor of the Company, details of which are set out in "Relationship with the Controlling Shareholder";
- (b) a non-competition and exclusive sales agency agreement in respect of radioactive-source-based instruments, isotope and irradiation business dated August 5, 2016 entered into between the Company and NPIC, pursuant to which NPIC agreed to, among others, provide certain non-competition undertakings in favor of the Company, details of which are set out in "Relationship with the Controlling Shareholder";
- (c) a non-competition and strategic cooperation agreement in terms of irradiation business dated August 12, 2016 entered into between the Company and CIRP, pursuant to which CIRP agreed to, among others, provide certain non-competition undertakings in favor of the Company, details of which are set out in "Relationship with the Controlling Shareholder";
- (d) a non-competition and exclusive sales cooperation agreement in terms of isotope and radioactive sources business dated August 18, 2016 entered into between the Company and 404 Company, pursuant to which 404 Company agreed to, among others, provide certain non-competition undertakings in favor of the Company, details of which are set out in "Relationship with the Controlling Shareholder";







- (e) a non-competition agreement dated August 18, 2016 entered into between the Company and CNEIC, pursuant to which CNEIC agreed to, among others, provide certain non-competition undertakings in favor of the Company, details of which are set out in “Relationship with the Controlling Shareholder”;
- (f) a capital contribution agreement in relation to the Company dated December 21, 2016 entered into among the Company, CNNC, CIAE, NPIC, CNNC Fund, 404 Company, Baoyuan Investment, CAIF and CAIC, pursuant to which CNNC, CIAE, NPIC, CNNC Fund, 404 Company, Baoyuan Investment, CAIF and CAIC agreed to inject capital and subscribe ordinary shares of the Company for a total consideration of RMB850 million, details of which are set out in “History, Development and Corporate Structure”;
- (g) the Non-competition Undertaking dated June 16, 2018 issued by CNNC to our Company, details of which are set out in “Relationship with the Controlling Shareholder”;
- (h) a cornerstone investment agreement dated June 19, 2018 entered into among the Company, Sure Advance Holdings Limited (通程控股有限公司), China International Capital Corporation Hong Kong Securities Limited (中國國際金融香港證券有限公司) and CLSA Limited (中信里昂證券有限公司), pursuant to which Sure Advance Holdings Limited agreed to subscribe for 11,906,400 H Shares at the Offer Price, details of which are set out in “Cornerstone Investors”;
- (i) a cornerstone investment agreement dated June 19, 2018 entered into among the Company, Shanghai Pharmaceuticals (HK) Investment Limited (上海醫藥(香港)投資有限公司), China International Capital Corporation Hong Kong Securities Limited (中國國際金融香港證券有限公司) and CLSA Limited (中信里昂證券有限公司), pursuant to which Shanghai Pharmaceuticals (HK) Investment Limited agreed to subscribe for 8,006,000 H Shares at the Offer Price, details of which are set out in “Cornerstone Investors”;
- (j) a cornerstone investment agreement dated June 19, 2018 entered into among the Company, Beijing Industrial Developing Investment Management Co., Ltd. (北京工業發展投資管理有限公司), China International Capital Corporation Hong Kong Securities Limited (中國國際金融香港證券有限公司) and CLSA Limited (中信里昂證券有限公司), pursuant to which Beijing Industrial Developing Investment Management Co., Ltd. agreed to subscribe for such number of H Shares in the amount of HK dollars equivalent to USD30,000,000 (excluding the brokerage, the SFC transaction levy and the Stock Exchange trading fee payable) at the Offer Price, details of which are set out in “Cornerstone Investors”;
- (k) a cornerstone investment agreement dated June 19, 2018 entered into among the Company, China Structural Reform Fund Corporation Limited (中國國有企業結構調整基金股份有限公司), China International Capital Corporation Hong Kong Securities Limited (中國國際金融香港證券有限公司) and CLSA Limited (中信里昂證券有限公司), pursuant to which China Structural Reform Fund Corporation Limited agreed to subscribe for such number of H Shares in the amount of HK dollars equivalent to USD30,000,000 (including the brokerage, the SFC transaction levy and the Stock Exchange trading fee payable) at the Offer Price which in any event shall not exceed 15,993,600 H Shares, details of which are set out in “Cornerstone Investors”; and
- (l) the Hong Kong Underwriting Agreement.

B. Our Intellectual Property Rights**(a) Trademarks**




Trademarks in Relation to Our Business

As of the Latest Practicable Date, we had the following trademarks which we consider to be material in relation to our businesses:

S/N	Name of Trademark	Registration number	Owner of the registration	Classification number	Valid duration
1		672466	HTA	1	2014.1.7-2024.1.6
2		671266	HTA	1	2013.12.28-2023.12.27
3		151191	HTA	5	2013.3.1-2023.2.28
4	原子高科	18204424	HTA	1	2016.12.7-2026.12.6
5	原子高科	18204965	HTA	5	2016.12.7-2026.12.6
6	原子高科	18204121	HTA	9	2016.12.7-2026.12.6
7	原子高科	18204670	HTA	10	2016.12.7-2026.12.6
8	原子高科	18203821	HTA	35	2017.2.21-2027.2.20
9	弗唐派特	5020289	Shanghai Yuanzi Kexing	5	2009.4.28-2019.4.27
10	思通宁	4529566	Shanghai Yuanzi Kexing	5	2008.6.28-2018.6.27
11	IOC	1468506	Shanghai Yuanzi Kexing	5	2010.11.7-2020.11.6
12	原子科兴	12140335	Shanghai Yuanzi Kexing	35	2014.7.28-2024.7.27
13	原子科兴	12193605	Shanghai Yuanzi Kexing	5	2014.8.7-2024.8.6
14	思通宁	12140315	Shanghai Yuanzi Kexing	35	2014.7.28-2024.7.27
15	弗唐派特	12140326	Shanghai Yuanzi Kexing	35	2014.7.28-2024.7.27
16	IOC	12139993	Shanghai Yuanzi Kexing	35	2014.7.28-2024.7.27
17		3324897	CNGT	5	2014.6.21-2024.6.20
18		3739982	CNGT	5	2016.6.7-2026.6.6
19	ISOTOPE 希典	3739983	CNGT	5	2016.3.21-2026.3.20
20		5130227	CNGT	5	2009.6.7-2019.6.6
21		1455708	BNIBT	35	2010.10.7-2020.10.6
22		1472571	BNIBT	5	2010.11.14-2020.11.13

S/N	Name of Trademark	Registration number	Owner of the registration	Classification number	Valid duration
23		4117904	BNIBT	5	2017.3.28-2027.3.27
24		5969176	CIC Lab	44	2010.3.7-2020.3.6
25		6448105	Headway	10	2010.3.7-2020.3.6
26		1480629	Headway	5	2010.11.28-2020.11.27
27		1523320	Headway	10	2011.2.14-2021.2.13
28		1327108	Anhui Young-Hearty	10	2009.10.21-2019.10.20

The Trademarks Involved in the Trademark License Agreement

S/N	Name of Trademarks	Registration number	Owner of the registration	Classification number
1		303912886	CNNC, the Company	1,4,5,6,7,9,10,11,16,35,36,39,40,42,44
2		303912859	CNNC, the Company	1,4,5,6,7,9,10,11,16,35,36,39,40,42,44
3		303912877	CNNC, the Company	1,4,5,6,7,9,10,11,16,35,36,39,40,42,44

(b) Patents

As of the Latest Practicable Date, we had the following patents in the PRC which we consider to be material in relation to our businesses:

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
1	200810085016.1	Components of heavy water reactor cobalt	Shanghai Nuclear Engineering Research and Design Institute, issuer	Invention	2008.3.13	2011.3.2
2	201020243252.4	Cobalt-source transport container	China Nuclear Power Engineering Co., Ltd, issuer, Dalian Tianrui Electrical and Mechanical Equipment Co., Ltd.	Utility model	2010.6.30	2011.6.22
3	200820005378.0	A neutron source rod loading bucket type protective device.	Nuclear Power Qinshan Joint Venture Co., Ltd, issuer, NPIC	Utility model	2008.3.13	2008.12.17
4	201620744686.X	Automated Radioactivity Activity Measurement Device	HTA	Utility model	2016.7.14	2016.12.14
5	201620744688.9	Semi-automatic the aluminum cap of penicillin bottle opening device	HTA	Utility model	2016.7.14	2016.12.14
6	201310228023.3	A type of scan mobile device for tower fault detection	HTA	Invention	2013.6.8	2016.2.3

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
7	201310750963.9	A type of radioactive particle chain	HTA	Invention	2013.12.31	2016.1.20
8	201110332635.8	85Kr source preparation and recovery process	HTA	Invention	2011.10.28	2015.12.9
9	201210166875.X	A type of Chromatographic column device use for generator	HTA	Invention	2012.5.28	2015.12.9
10	201310663321.5	A type of source core carrier of radioactive particle and its preparation process	HTA	Invention	2013.12.10	2015.9.23
11	201310228027.1	A type of crude oil samples for oilfield interwell tracer technique taking 19 samples of devices	HTA	Invention	2013.6.8	2015.8.5
12	201210560551.4	A type of irradiated crumb rubber modified asphalt and Its preparation method	HTA	Invention	2012.12.21	2015.4.8
13	201110193303.6	A radioactive labeled laminating ceramic proppant and its preparation method	HTA	Invention	2011.7.12	2013.8.14
14	201110200074.6	A type of method for preparing radioactive 68Ge solution	HTA	Invention	2011.7.18	2013.8.14
15	201110106810.1	A type of determination of thyroid-stimulating hormone for long optical path enzyme-linked immunoassay and kits.	HTA	Invention	2011.4.27	2012.11.28
16	201010104697.9	A type of 68Ge line source for attenuation correction of PET preparation process	HTA	Invention	2010.2.3	2012.7.25
17	201010104700.7	Palladium-103 and iodine-125 composite brachytherapy source, source cores and it's preparation method	HTA	Invention	2010.2.3	2012.3.7
18	201010212968.2	103Pd brachytherapy source cores preparation technology	HTA	Invention	2010.6.30	2011.12.7
19	200610076777.1	Neutron spectrum well logging system	HTA	Invention	2006.4.20	2009.10.21
20	201410323377.0	A type of composited nuclide radioactive Stent and its preparation method	HTA	Invention	2014.7.8	2016.8.17
21	201410323239.2	A type of radioactive Stent and its preparation method	HTA	Invention	2014.7.8	2016.6.8
22	201310750640.X	A type of method for preparing radioactive particle chains	HTA	Invention	2013.12.31	2016.8.17
23	201310228008.9	A type of water sample extraction device used for oilfield interwell tracer technique	HTA	Invention	2013.6.8	2016.9.14
24	201520465395.2	Iodine 131 diagnostic capsule sorting Packaging table	HTA	Utility model	2015.7.1	2015.11.18
25	201520484572.1	A type of foam packing box	HTA	Utility model	2015.7.7	2015.11.18
26	201520399456.X	A type of agitator	HTA	Utility model	2015.6.11	2015.10.14
27	201520465407.1	Iodine 131 diagnostic capsule activity measuring instrument	HTA	Utility model	2015.7.1	2015.10.14
28	201420458727.X	A type of reaction bulb	HTA	Utility model	2014.8.14	2014.12.10
29	201320331135.7	A type of isotope tracer injection device used for oilfield inter-fell tracer technique	HTA	Utility model	2013.6.8	2014.1.22
30	201320330728.1	A type of water sample extraction device used for oilfield interwell tracer technique	HTA	Utility model	2013.6.8	2014.1.8
31	201320276359.2	Line type germanium 68 calibration source pot-type equipment.	HTA	Utility model	2013.5.20	2013.12.18
32	201320276361.X	Line type germanium 68 calibration Source scanner and detector	HTA	Utility model	2013.5.20	2013.11.13
33	201120331593.1	A type of nuclear reactors is used to store a transport container with primary neutron source	HTA	Utility model	2011.9.6	2012.5.30
34	201120292446.8	vehicle Radiation Source monitoring and guard system	HTA	Utility model	2011.8.12	2012.5.23
35	201120243652.X	Radioactive tagged sand injection equipment	HTA	Utility model	2011.7.12	2012.4.25

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
36	201020109401.8	Isotopic tracer wellhead plug-in injection equipment	HTA	Utility model	2010.2.8	2010.10.6
37	200710039985.9	Benzothiazole aniline Compounds and its preparation method and application.	Shanghai Yuanzi Kexing	Invention	2007.4.25	2010.12.15
38	200710103614.2	A type of 18F fluorine labeled purine compounds and its preparation method and application.	Shanghai Yuanzi Kexing	Invention	2007.4.28	2009.7.1
39	201110224661.9	Composite of 1,4 trans-disubstituted triazole structure of 188Re(CO) ₃ labeled compounds	Shanghai Yuanzi Kexing	Invention	2011.8.5	2014.12.10
40	201110224721.7	A type of preparation method comprises 1,4-trans-disubstituted triazole structure of 18F labeled compounds	Shanghai Yuanzi Kexing	Invention	2011.8.5	2014.7.30
41	201110226095.5	A type of improvement of cyclotron ion source system	Shanghai Yuanzi Kexing	Invention	2011.8.8	2015.10.28
42	201110226236.3	A type of grooved radiopharmaceutical charging box	Shanghai Yuanzi Kexing	Invention	2011.8.9	2015.5.13
43	201110228912.0	A type of cyclotron target in-house simulation target system	Shanghai Yuanzi Kexing	Invention	2011.8.10	2016.1.13
44	201110228976.0	A type of Automatic split charging method for radiopharmaceutical.	Shanghai Yuanzi Kexing	Invention	2011.8.10	2015.2.11
45	201120282295.8	A type of measuring device of radioactive contamination.	Shanghai Yuanzi Kexing	Utility model	2011.8.4	2012.5.9
46	201120282310.9	A type of absorption equipment for parallel activated carbon	Shanghai Yuanzi Kexing	Utility model	2011.8.4	2012.5.9
47	201120286194.8	A type of improved Ion Source system used in the cyclotron	Shanghai Yuanzi Kexing	Utility model	2011.8.8	2012.2.22
48	201120286312.5	Safe and reliable amplifier high-voltage power source	Shanghai Yuanzi Kexing	Utility model	2011.8.9	2012.4.11
49	201120286353.4	A type of split charging box used for radiopharmaceutical	Shanghai Yuanzi Kexing	Utility model	2011.8.9	2012.5.9
50	201120286577.5	Thermoluminescence measuring device	Shanghai Yuanzi Kexing	Utility model	2011.8.9	2012.10.10
51	201120286598.7	A type of system used for a new type boiling of drug equipment	Shanghai Yuanzi Kexing	Utility model	2011.8.9	2012.5.23
52	201120289729.7	A type of system used for production of radiopharmaceutical simulated target	Shanghai Yuanzi Kexing	Utility model	2011.8.10	2012.5.9
53	201120291864.5	A type of clean bench	Shanghai Yuanzi Kexing	Utility model	2011.8.11	2012.5.23
54	201210398580.5	A type of cyclotron beam current measuring device	Shanghai Yuanzi Kexing	Invention	2012.10.18	2016.6.8
55	201310106821.9	The RGD lipid peptides PET of Targeting integrin $\alpha \nu \beta 3$ imaging agents	Shanghai Yuanzi Kexing	Invention	2013.3.28	2015.10.28
56	201410002006.2	A type of high pressure steam sterilization equipment.	Shanghai Yuanzi Kexing	Invention	2014.1.2	2016.6.8
57	201410002009.6	Prepared long-term effective method for technetium 99mTc Methylene diphosphonate injection drug	Shanghai Yuanzi Kexing	Invention	2014.1.2	2015.10.28
58	201410205820.4	A type of FDG target system	Shanghai Yuanzi Kexing	Invention	2014.5.15	2016.4.6
59	201420002517.X	A type of electron tube cooling water connection	Shanghai Yuanzi Kexing	Utility model	2014.1.2	2014.7.2
60	201420002569.7	A type of protective device in the course of technetium drug labeling	Shanghai Yuanzi Kexing	Utility model	2014.1.2	2014.7.2
61	201420231205.6	A type of radiation protective device used for fume hood	Shanghai Yuanzi Kexing	Utility model	2014.5.7	2014.10.15
62	201420231666.3	A type of supper clean equipment for decompression condition	Shanghai Yuanzi Kexing	Utility model	2014.5.7	2014.10.15

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
63	201520310910.X	A type of improved 18F-NaF automatic synthesis module	Shanghai Yuanzi Kexing	Utility model	2015.5.14	2015.12.9
64	201520319998.1	A type of improved technetium drug Administering medications channel	Shanghai Yuanzi Kexing	Utility model	2015.5.18	2015.10.7
65	201520320013.7	A type of improved deflection beam current measurement system	Shanghai Yuanzi Kexing	Utility model	2015.5.18	2015.9.23
66	201520945162.2	A type of anti-radiation protective lead-glass equipment	Shanghai Yuanzi Kexing	Utility model	2015.11.24	2016.4.20
67	201520945187.2	A type of institution used for protection lead jar onlays to slip	Shanghai Yuanzi Kexing	Utility model	2015.11.24	2016.4.20
68	201520956259.3	A type of radiometric isotope drug Loading system	Shanghai Yuanzi Kexing	Utility model	2015.11.26	2016.4.27
69	201520956636.3	A type of distillation equipment used for radiopharmaceutical isolation and purification	Shanghai Yuanzi Kexing	Utility model	2015.11.26	2016.4.27
70	201520956639.7	A separation column used for purification and copper removal	Shanghai Yuanzi Kexing	Utility model	2015.11.26	2016.4.27
71	201520956651.8	A separation column used for 18F-FDG purification	Shanghai Yuanzi Kexing	Utility model	2015.11.26	2016.4.27
72	201520962222.1	A of radiometric isotope drug Loading system	Shanghai Yuanzi Kexing, Shanghai Rutian Packing Equipment Co., Ltd	Utility model	2015.11.26	2016.6.29
73	201620767263.X	A tube vacuum cleaning device	HTA (Guangzhou)	Utility model	2016.7.19	2017.1.11
74	201620767438.7	A radiation protection isolation wall	HTA (Guangzhou)	Utility model	2016.7.19	2016.12.14
75	201620767464.X	A lead protective body	HTA (Guangzhou)	Utility model	2016.7.19	2016.12.14
76	201620770123.8	A transfer mechanism for radioactive reagent	HTA (Guangzhou)	Utility model	2016.7.19	2016.12.14
77	201620767460.1	A radioactive reagent delivery channel	HTA (Guangzhou)	Utility model	2016.7.19	2016.12.14
78	201420552852.7	An omnibearing disguised item transfer window	HTA (Guangzhou)	Utility model	2014.9.24	2015.3.4
79	201420552733.1	A delivery channel equipped with optional air shower head	HTA (Guangzhou)	Utility model	2014.9.24	2015.3.4
80	201420575877.9	Portable radioactive isotope transport case	HTA (Guangzhou)	Utility model	2014.9.30	2015.3.4
81	201420576188.X	Radionuclide work console	HTA (Guangzhou)	Utility model	2014.9.30	2015.3.4
82	201420552646.6	A storage tube for radioactive reagents	HTA (Guangzhou)	Utility model	2014.9.24	2015.3.4
83	201420576294.8	Radioactive isotope product transport cart	HTA (Guangzhou)	Utility model	2014.9.30	2015.3.4
84	201420575644.9	New radioactive isotope multi-batch operation waste storage box	HTA (Guangzhou)	Utility model	2014.9.30	2015.3.4
85	201420575863.7	Efficient radioactive isotope labeling reaction boiling water bath container	HTA (Guangzhou)	Utility model	2014.9.30	2015.1.28
86	201420575651.9	Ultra-clean radiation shielding fume hood	HTA (Guangzhou)	Utility model	2014.9.30	2015.1.28
87	201310119972.8	A method for the determination of radioactive chemical purity of a technetium 99mTc pentetate acid salt injection	HTA (Guangzhou)	Invention	2013.4.9	2014.6.4
88	201020685386.1	Radiation source braiding hydraulic shearing device	CNGT	Utility model	2010.12.28	2011.9.21

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
89	201020617329.X	Radiation source braiding hydraulic connection device	CNGT	Utility model	2010.11.19	2011.8.24
90	201020617287.X	γ knife source loading basket	CNGT	Utility model	2010.11.19	2011.8.24
91	201020617564.7	Cobalt particle collection device	CNGT	Utility model	2010.11.22	2011.8.24
92	201020617316.2	γ knife radiation source transport container	CNGT	Utility model	2010.11.19	2011.7.20
93	201020617304.X	Xenon target used for nuclear reactor irradiation to produce iodine-125	CNGT	Utility model	2010.11.19	2011.7.20
94	201020685468.6	Medical radioactive source sub packaging scanning detection device	CNGT	Utility model	2010.12.28	2011.8.24
95	201020685373.4	Radiation seed source vacuum suction device	CNGT	Utility model	2010.12.28	2011.10.05
96	201220299567.X	Low radioactivity cobalt-60 rod material source	CNGT	Utility model	2012.6.26	2013.2.20
97	201220299408.X	New type after-loading cobalt-60 γ source for therapy	CNGT	Utility model	2012.6.26	2013.1.16
98	201230277751.X	Packing-case (strontium chloride [89Sr] injection)	CNGT	Appearance design	2012.6.27	2012.10.31
99	201420838744.6	Cobalt-60 radioactive source for gamma knife radiotherapy systems	CNGT	Utility model	2014.12.25	2015.4.08
100	201420453554.2	A quick collection device for high concentration radioactive solutions	CNGT	Utility model	2014.8.12	2014.12.03
101	201320574040.8	Vacuum bottle batch preparation device	CNGT	Utility model	2013.9.16	2014.2.12
102	200810182829.2	Beta particle hemorrhoid treatment instrument	BNIBT	Invention	2008.12.10	2012.1.25
103	201210153802.7	Method for isolating I-type procollagen amino-terminal peptide	BNIBT	Invention	2012.5.18	2014.6.25
104	201210054083.3	Purified antibody with immunoaffinity precipitation method	BNIBT	Invention	2012.3.5	2015.5.20
105	201210125220.8	Chemiluminescence quantitative detection kit for Hyaluronic acid with one-step method	BNIBT	Invention	2012.4.26	2014.12.10
106	201210125222.7	A kit for rapid detection of hepatitis A virus IgM antibody and its preparation method	BNIBT	Invention	2012.4.26	2015.2.4
107	201210153804.6	A method for preparing solid phase antibodies for immunoassay	BNIBT	Invention	2012.5.18	2015.9.16
108	201110332420.6	Cleaning machine for automatic cleaning of the radiographic analysis tube or coated pearl	BNIBT	Invention	2011.10.27	2013.11.13
109	201320641744.2	Low-energy photonic skin applicator	BNIBT	Utility model	2013.10.18	2016.4.6
110	201420852731.4	Flexible iodine-125 low energy photonic skin applicator	BNIBT	Utility model	2014.12.30	2015.11.25
111	200610062711.7	Non-toxic environmental scintillation solution	Headway	Invention	2006.9.20	2010.8.25
112	200810065667.4	A device for collecting carbon dioxide gas	Headway	Invention	2008.1.25	2011.12.14
113	200920133915.4	Medical bottle opener	Headway	Utility model	2009.7.15	2010.4.21
114	201310110152.2	A gas sampling bag and its manufacturing method	Headway	Invention	2013.3.29	2016.1.20
115	201020271083.5	Helicobacter pylori 14C detection device	Headway	Utility model	2010.7.26	2011.6.1
116	201010232783.8	Urea 14C capsules and the micro scale sub package methods	Headway	Invention	2010.7.21	2013.1.30
117	201010236770.8	A gas sampling bag for breath test	Headway	Invention	2010.7.26	2013.4.4
118	201020271002.1	A gas sampling bag for breath test	Headway	Utility model	2010.7.26	2011.6.22
119	201030253662.2	Gas sampling bag	Headway	Appearance design	2010.7.26	2011.4.13
120	201020613085.8	A gas sampling bag for breath test	Headway	Utility model	2010.11.18	2011.6.22
121	201030619718.1	Gas sampling bag	Headway	Appearance design	2010.11.18	2011.5.4

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
122	201320156351.2	A gas sampling bag	Headway	Utility model	2013.3.29	2013.10.30
123	201520660944.1	A portable sphygmomanometer	Anhui Young-Hearty	Utility model	2015.8.27	2016.12.21
124	201521089266.4	A new type vacuum blood collection tube	Anhui Young-Hearty	Utility model	2015.12.23	2016.12.21
125	201520660573.7	An integrated portable blood glucose meter	Anhui Young-Hearty	Utility model	2015.8.27	2016.12.14
126	201510145328.7	Cartridge Detector with automatic sampling device	Anhui Young-Hearty	Invention	2015.3.27	2016.10.19
127	201521083330.8	An infusion tube	Anhui Young-Hearty	Utility model	2015.12.22	2016.9.14
128	201520953871.5	A medical use portable LED light	Anhui Young-Hearty	Utility model	2015.11.25	2016.8.10
129	201521089255.6	A medical infusion stand	Anhui Young-Hearty	Utility model	2015.12.23	2016.8.10
130	201521089259.4	A medical device holding device	Anhui Young-Hearty	Utility model	2015.12.23	2016.6.1
131	201521076563.5	A new type illuminable tooth extraction pliers	Anhui Young-Hearty	Utility model	2015.12.21	2016.6.1
132	201521078504.1	A thermometer	Anhui Young-Hearty	Utility model	2015.12.22	2016.6.1
133	201520949909.1	A shell of a wearable electronic device wore on the wrist	Anhui Young-Hearty	Utility model	2015.11.24	2016.5.4
134	201520963132.4	A multi-function drip rack	Anhui Young-Hearty	Utility model	2015.11.25	2016.5.4
135	201520948850.4	A wearable Internet of things device for pregnant women's guarding and alarming	Anhui Young-Hearty	Utility model	2015.11.24	2016.5.4
136	201520953873.4	An antiseptic Helicobacter pylori detector	Anhui Young-Hearty	Utility model	2015.11.25	2016.5.4
137	201020160220.8	Fiber optic adapter	Anhui Young-Hearty	Utility model	2010.3.20	2011.1.5
138	201020177384.1	Optical fiber connector:	Anhui Young-Hearty	Utility model	2010.4.5	2011.3.29
139	201020267398.2	Breath sampling bag	Anhui Young-Hearty	Utility model	2010.7.17	2011.2.2
140	201320033037.5	Breath sampling device	Anhui Young-Hearty	Utility model	2013.1.11	2013.8.14
141	201320539099.3	A portable breath card detector	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
142	201320539055.0	A smoke removal device of laser cutting machine	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
143	201320539052.7	An exhalation card storage device	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
144	201320539053.1	A turntable slot stand	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
145	201320539104.0	A breath card stacking device	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
146	201320539098.9	A cloth feeding stand	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
147	201320539042.3	A Cylindrical device for carbon XIII Infrared Spectrometer	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
148	201320539041.9	A Y-type three-way component	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
149	201320539066.9	A drying system for air dry oven	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
150	201320539070.5	A filter device for air conditioner	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
151	201320539103.6	A filter device for air conditioner	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
152	201320539100.2	An improved air dry oven drying system	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
153	201320539097.4	A baking system for air dry oven	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
154	201320539102.1	A new type of water removal system	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
155	201320539101.7	A unwatering system for air dry oven	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
156	201320539068.8	A host surface of the carbon XIII infrared spectrometer	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
157	201320539043.8	A dual channel detector	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
158	201320539044.2	A breath card detector	Anhui Young-Hearty	Utility model	2013.8.30	2014.3.19
159	201320539096.X	A dehumidification circulation system for air dry oven	Anhui Young-Hearty	Utility model	2013.8.30	2014.6.25
160	201420738488.3	A small oxygen supply device	Anhui Young-Hearty	Utility model	2014.11.27	2015.4.29
161	201420731514.X	A breathing machine Humidifying device	Anhui Young-Hearty	Utility model	2014.11.27	2015.8.5
162	201520185898.4	Infrared spectrometer	Anhui Young-Hearty	Utility model	2015.3.27	2015.8.5

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
163	201520185984.5	Solid scintillation vials	Anhui Young-Hearty	Utility model	2015.3.27	2015.8.5
164	201520185939.X	Liquid scintillation detector with automated injection device	Anhui Young-Hearty	Utility model	2015.3.27	2015.11.4
165	201520185889.5	Liquid scintillation counter	Anhui Young-Hearty	Utility model	2015.3.27	2016.3.30
166	201520656820.6	A medicine storage box	Anhui Young-Hearty	Utility model	2015.8.27	2016.1.20
167	201520656685.5	A traditional Chinese medicine mashing device	Anhui Young-Hearty	Utility model	2015.8.27	2016.4.6
168	201520865944.5	A three-card type helicobacter pylori detector	Anhui Young-Hearty	Utility model	2015.10.31	2016.4.13
169	201520865943.0	A medical instrument rack	Anhui Young-Hearty	Utility model	2015.10.31	2016.4.13
170	201520922296.2	An infusion drips device	Anhui Young-Hearty	Utility model	2015.11.17	2016.4.13
171	201520933620.0	A care pallet security device	Anhui Young-Hearty	Utility model	2015.11.19	2016.4.13
172	201520949937.3	A wearable electronic device wore on the wrist	Anhui Young-Hearty	Utility model	2015.11.24	2016.4.13
173	201620501206.7	High sensitivity personal dose alarm	BINE	Utility model	2016.5.27	2016.12.14
174	201620501267.3	A new type of measurement data acquisition and detection system	BINE, Shanghai JPY Ion Tech Co., Ltd.	Utility model	2016.5.27	2016.12.14
175	201620501340.7	A source rack operation indicator bit signal device	BINE, Shanghai JPY Ion Tech Co., Ltd.	Utility model	2016.5.27	2016.12.14
176	201020102390.0	Single Channel Six-way source New γ Irradiation Device	BINE, Tianjin JPY Ion Tech Co., Ltd.	Utility model	2010.1.27	2010.12.8
177	201120131769.9	A new type of radiation resistant lens	BINE	Utility model	2011.4.29	2011.11.9
178	201120132751.0	A new type of γ -irradiation mobile monitoring device	BINE, Tianjin JPY Ion Tech Co., Ltd.	Utility model	2011.4.29	2011.12.28
179	201120132823.1	A new type of irradiation door anti-opening device	BINE	Utility model	2011.4.29	2011.12.28
180	201120132845.8	A multi-task monitoring system for irradiation devices	BINE, Tianjin JPY Ion Tech Co., Ltd.	Utility model	2011.4.29	2011.11.9
181	201220322829.X	A source frame anti-collision device	BINE	Utility model	2012.7.4	2013.5.1
182	201220332915.9	A photoelectric switch inspection and verification device	BINE	Utility model	2012.7.10	2013.7.10
183	201220333365.2	A irradiation box door detection device	BINE	Utility model	2012.7.10	2013.5.1
184	201320675397.5	A long rod tool socket type coupling mechanism	BINE, Zhongjin Irradiation (Wuhan) Incorporated Company	Utility model	2013.10.29	2014.5.7
185	201120132080.8	An irradiation device spray system	BINE, Tianjin JPY Ion Tech Co., Ltd.	Utility model	2011.4.29	2011.12.28
186	201120132824.6	A new type irradiation product test device	BINE	Utility model	2011.4.29	2011.11.9
187	201220323115.0	A new type irradiation device electric push tank mechanism	BINE	Utility model	2012.7.4	2013.5.22
188	201320671861.3	Multi-detector enhanced chain-type dose detector	BINE, Tianjin JPY Ion Tech Co., Ltd., Zhongjin Irradiation (Wuhan) Incorporated Company	Utility model	2013.10.29	2014.05.07
189	201320687833.0	A new type of irradiation box removal trolley assembly	BINE	Utility model	2013.11.4	2014.5.7
190	201320688911.9	A smoke detection interlocking mechanism	BINE	Utility model	2013.11.4	2014.5.7
191	201110163609.7	A copolymer of polyurethane elastomer and hydrophilic compound and its preparation method	Sichuan Institute of Atomic Energy, Suzhou Radiation	Invention	2011.6.17	2012.11.28
192	201620271047.6	[18F]Sodium fluoride preparation device	HTA	Utility model	2016.4.1	2017.3.22
193	201510317469.2	A micro-emulsion polymerization method for preparing radioactive sources	HTA	Invention	2015.6.11	2017.9.12

S/N	Patent No.	Name of patent	Patentee	Patent type	Date of application	Date of authorization
194	201621237984.6	A welder feed device	HTA	Utility model	2016.11.18	2017.6.20
195	201720004480.8	Clamping device with adjustable clamping force	Yuanzi Gaoke Co., Ltd.	Utility model	2017.1.4	2017.8.8
196	201621244412.0	A radioactive isotope generator chromatographic column holder device	Yuanzi Gaoke Co., Ltd.	Utility model	2016.11.18	2017.8.8
197	201630561844.3	Radioisotope generator protection container	Yuanzi Gaoke Co., Ltd.	Appearance	2016.11.19	2017.6.20
198	201621004936.2	A liquid nitrogen device for gamma spectrometer	Shanghai Yuanzi Kexing	Utility model	2016.8.30	2017.3.22
199	201621013395.X	A radioactive chemical purity chromatography cartridge	Shanghai Yuanzi Kexing	Utility model	2016.8.30	2017.3.22
200	201621012791.0	A Cyclone 30 accelerator electrostatic deflection plate electrode mounting device	Shanghai Yuanzi Kexing	Utility model	2016.8.30	2017.4.12
201	201510245345.8	Sulfonamides targeted to carbonic anhydrase IX, intermediates, preparation and application	Shanghai Yuanzi Kexing	Invention	2015.5.14	2017.10.17
202	201720422077.7	A breath detection air bag vacuum machine	Headway	Utility model	2017.4.20	2017.11.24
203	201730115057.0	Ionization helicobacter pylori tester (HP)	Headway	Appearance design	2017.4.10	2017.9.12
204	201730115059.X	Ionization helicobacter pylori tester (HP)	Headway	Appearance design	2017.4.10	2017.9.12
205	201720360773.X	A liquid flashed helicobacter pylori tester	Headway	Utility model	2017.4.7	2017.12.19
206	201620499313.0	A new type of differential roller head or tail wheel assembly transmission light wheel components	BINE, Shanghai JPY Ion Tech Co., Ltd.	Utility model	2016.5.27	2017.10.10
207	200510125983.2	A method for producing a natural rubber latex with low soluble protein content	Suzhou Radiation	Invention	2005.12.1	2008.7.2

(c) Software copyright

As of the Latest Practicable Date, the Group had the following soft copyrights which we consider to be material in relation to our businesses:

S/N	Name of copyright	Owners of copyright	Date of development completion	First publication date	Registration No.	Acquiring method of the right	Scope of right
1	Yuanzi Hi-Tech Integrated Drug Management Software V1.0	HTA	2010.8.9	2010.8.9	2011SR075477	Original acquisition	All rights
2	Yuanzi Hi-Tech materials storage and retrieval management information software V1.0	HTA	2010.2.25	2010.2.25	2011SR075476	Original acquisition	All rights
3	Yuanzi Hi-Tech aggregate albumin injection reaction conditions fine control software V1.0	HTA	2009.11.7	2009.11.7	2011SR075609	Original acquisition	All rights
4	Yuanzi Hi-Tech injection weight fine control software V1.0	HTA	2010.5.10	2010.5.10	2011SR075607	Original acquisition	All rights
5	Yuanzi Hi-Tech Pharmaceutical Control Software V1.0	HTA	2009.7.8	2009.7.8	2011SR076657	Original acquisition	All rights
6	Yuanzi Hi-Tech liquid production temperature control software V1.0	HTA	2009.5.15	2009.5.15	2011SR077063	Original acquisition	All rights
7	Headway breath test instrument control software V1.0.0	Headway	2014.12.29	Unpublished	2015SR151569	Original acquisition	All rights
8	Headway helicobacter pylori tester (card) control software V1.0.0	Headway	2013.12.31	Unpublished	2015SR151565	Original acquisition	All rights
9	Headway helicobacter pylori tester (Liquid flash) control software V1.0.0	Headway	2013.12.31	Unpublished	2015SR151563	Original acquisition	All rights

S/N	Name of copyright	Owners of copyright	Date of development completion	First publication date	Registration No.	Acquiring method of the right	Scope of right
10	Yanghe helicobacter pylori detector control software V1.0	Anhui Young-Hearty	—	2006.4.20	2007SR15190	Original acquisition	All rights
11	Yanghe YH630 semiconductor laser treatment system V2.0	Anhui Young-Hearty	—	2008.6.2	2008SR17538	Original acquisition	All rights
12	Yanghe 13C infrared spectrometer control software V1.0	Anhui Young-Hearty	2010.8.11	2010.8.11	2010SR057979	Original acquisition	All rights
13	Yanghe YH04E type helicobacter pylori detector control software V1.0	Anhui Young-Hearty	2011.8.1	Unpublished	2011SR077679	Original acquisition	All rights
14	Yanghe 14C liquid scintillation counter control software V1.0	Anhui Young-Hearty	2013.3.1	2013.6.17	2013SR139208	Original acquisition	All rights
15	Yanghe YH08A type 13C infrared spectrometer control software V1.0.0	Anhui Young-Hearty	2013.2.1	2013.6.13	2016SR026701	Original acquisition	All rights
16	Irradiation device radioactive source arrangement software	BINE	2012.5.27	2012.5.27	2013SR094851	Original acquisition	All rights
17	BFT gamma irradiation device control system	BINE	2012.3.3	Unpublished	2012SR091612	Original acquisition	All rights
18	Yanghe YH04AS type automatic sampling helicobacter pylori tester control software with card V1.0.0	Anhui Young-Hearty	2016.8.23	2016.11.25	2017SR115329	Original acquisition	All rights
19	Yanghe YH01AS type automatic sampling liquid scintillation counter control software V1.0.0	Anhui Young-Hearty	2013.11.1	2013.12.4	2017SR115750	Original acquisition	All rights
20	Zhongtong Lanbo microorganism metabolism element information management system V1.0	CIC Lab	2016.11.15	2017.2.23	2017SR242290	Original acquisition	All rights
21	Zhongtong Lanbo lab S1S management information system V1.0	CIC Lab	2017.1.12	2017.2.22	2017SR242355	Original acquisition	All rights
22	Zhongtong Lanbo medical information survey, analysis and management software V1.0	CIC Lab	2016.9.21	2016.10.18	2017SR242419	Original acquisition	All rights
23	Zhongtong Lanbo microorganism multiple testing management and control software V1.0	CIC Lab	2016.8.26	2016.9.29	2017SR239593	Original acquisition	All rights
24	Zhongtong Lanbo gene diagnosis data analysis software V1.0	CIC Lab	2016.4.14	2016.7.19	2017SR239565	Original acquisition	All rights
25	Zhongtong Lanbo microorganism sampling, testing and analysis software V1.0	CIC Lab	2016.10.10	2016.11.22	2017SR239675	Original acquisition	All rights

3. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUPERVISORS

A. Particulars of Directors' and Supervisors' Contracts

Each of the executive Directors, non-executive Directors and independent non-executive Directors has entered into a service contract with our Company on June 16, 2018. These contracts contained the following contents (i) each contract is for a term of three years commencing from the Listing Date, and (ii) the contracts may be terminated by respective terms. The service contracts may be renewed in accordance with the Articles of Association and applicable laws, rules and regulations.

Pursuant to Rules 19A.54 and 19A.55 of the Listing Rules, we have entered into a contract with each of our Supervisors in respect of, among other things, (i) compliance of relevant laws and regulations, (ii) observations of the Articles of Association, and (iii) provisions on arbitration on June 16, 2018.

Save as disclosed above, none of our Directors or Supervisors has entered or has proposed to enter into any service agreements with our Company or any member of our Group (other than contracts expiring or determinable by the employer within one year without payment of compensation other than statutory compensation).

B. Directors' and Supervisors' Remuneration

In 2015, 2016 and 2017, the aggregate amount of fees, salaries, allowances, discretionary bonus, pension schemes contributions and other benefits in kind (if applicable) paid by our Company to our Directors were approximately RMB677,000, RMB210,000 and RMB2,150,000, respectively.

In 2015, 2016 and 2017, the aggregate amount of fees, salaries, allowances, discretionary bonus, pension schemes contributions and other benefits in kind (if applicable) paid by our Company to our Supervisors were approximately RMB1,271,000, RMB1,285,000 and RMB1,178,000, respectively.

Save as disclosed under Note 9 to the financial information in the Accountants' Report set out in Appendix I, no Director or Supervisor received other remuneration or benefits in kind from our Company in respect of the Track Record Period.

In accordance with the existing arrangements, the aggregate remuneration payable by our Company to our Directors and Supervisors for the year ending December 31, 2018 is approximately RMB300,000 and RMB1,094,885, respectively.

There is no arrangement under which any Director or Supervisors has waived or agreed to waive any remuneration or benefits in kind during the Track Record Period.

4. DISCLOSURE OF INTERESTS

A. Disclosure of Interests of Directors and Supervisors

Immediately following the completion of the Global Offering and assuming the Over-allotment Option is not exercised, none of our Directors, Supervisors and chief executive of our Company has any interest and/or short position in the shares, underlying shares and debentures of our Company or any associated corporation (within the meaning of Part XV of the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of SFO) or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers to be notified to us and the Stock Exchange (for this purpose, the relevant provisions of the SFO will be interpreted as if they applied to the Supervisors).

B. Disclosure of Substantial Shareholders

Save as disclosed in the section "Substantial Shareholders" of this Prospectus, our Directors, Supervisors and chief executive of our Company are not aware of any other person, not being a

Director, Supervisor, or chief executive of our Company, who has an interest or short position in the Shares and underlying Shares of our Company which, once our H Shares are listed, would fall to be disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who is, directly or indirectly, interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any member of our Group.

C. Disclaimers

Save as disclosed in this prospectus:

- (a) none of our Directors, Supervisors or chief executive of our Company has any interests and short positions in the shares, underlying shares and debentures of our Company or any associated corporation (within the meaning of Part XV of the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of SFO) or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or will be required, pursuant to the Model Code for Securities Transactions by Directors and Listed Companies to be notified to us and the Stock Exchange, in each case once our H Shares are listed. For this purpose, the relevant provisions of the SFO will be interpreted as if they applied to the Supervisors;
- (b) none of our Directors or Supervisors is a director or employee of a company which is expected to have an interest in the Shares falling to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO once our H Shares are listed on the Stock Exchange;
- (c) none of our Directors or Supervisors nor any of the parties listed in “— 5. OTHER INFORMATION — G. Qualification of Experts” of this Appendix is materially interested in any contract or arrangement subsisting at the date of this prospectus which is significant in relation to our business;
- (d) none of our Directors or Supervisors nor any of the parties listed in “— 5. OTHER INFORMATION — G. Qualification of Experts” of this Appendix is interested in our promotion, or in any assets which have, within the two years immediately preceding the issue of this prospectus, been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company;
- (e) none of the parties listed in “— 5. OTHER INFORMATION — G. Qualification of Experts” of this Appendix: (i) is interested legally or beneficially in any of our Shares or any shares in any of our subsidiaries; or (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities; and
- (f) none of our Directors or Supervisors or their respective associates or any Shareholders of our Company (who to the knowledge of our Directors owns more than 5% of our issued share capital) has any interest in our five largest suppliers or our five largest customers.

5. OTHER INFORMATION

A. Estate Duty

We have been advised that no material liability for estate duty under PRC law is likely to fall upon our Company or any member of our Group.

B. Litigation

Save as disclosed in this Prospectus, as of the Latest Practicable Date, we were not involved in any material litigation, arbitration or administrative proceedings, and as far as the Directors aware, none of any material litigation, arbitration or administrative proceedings to be pending or threatened against any member of the Group.

C. Sole Sponsor

The Sole Sponsor declared his independence in compliance with Rule 3A.07 of the Listing Rules.

The Sole Sponsor has made an application on behalf of our Company to the Listing Committee for listing of, and permission to deal in, the H Shares (including any Offer Shares that may be issued pursuant to the exercise of the Over-allotment Option). All necessary arrangements have been made to enable the H Shares to be admitted into CCASS.

We have entered into an engagement agreement with the Sole Sponsor, pursuant to which we agreed to pay a total amount of HK\$8,000,000 to the Sole Sponsor to act as the sponsor to our Company in the Global Offering.

D. Compliance Advisor

We have appointed China International Capital Corporation Hong Kong Securities Limited as our compliance advisor in compliance with Rule 3A.19 of the Listing Rules.

F. Promoters

The promoters of our Company are CNNC, CIAE and NPIC.

Save as disclosed in this prospectus, within the two years immediately preceding the date of this prospectus, no cash, securities or other benefit have been paid, allotted or given to the above promoters in connections with the Global Offering or related transactions in this prospectus.

G. Qualification of Experts

The qualifications of the experts, as defined under the Listing Rules, who have given their opinions or advice in this prospectus, are as follows:

<u>Name</u>	<u>Qualification</u>
China International Capital Corporation Hong Kong Securities Limited	Licensed to conduct Type 1 (Dealing in securities), Type 2 (Dealing in futures contracts), Type 4 (Advising on securities), Type 5 (Advising on futures contracts) and Type 6 (Advising on corporate finance) of the regulated activities as defined under the SFO
KPMG	Certified public accountants
King & Wood Mallesons	PRC legal advisors
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant

H. Consents of Experts

Each of the experts as referred to in “— 5. OTHER INFORMATION — G. Qualification of Experts” of this Appendix has given, and has not withdrawn, its respective written consents to the issue

of this prospectus with the inclusion of its report and/or letter and/or opinion and/or the references to its name included herein in the form and context in which it is respectively included.

Save as disclosed in this prospectus, none of the experts named above has any shareholding interests in any member of our Group or the right (other than the penal provisions) of sections 44A of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

I. Taxation of Holders of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer is effected on the H Share register of members of our Company, including in circumstances where such transaction is effected on the Stock Exchange. The current rate of Hong Kong stamp duty for such sale, purchase and transfer is a total of HK\$2.00 for every HK\$1,000 (or part thereof) of the consideration or, if higher, the fair value of the H Shares being sold or transferred. For further information in relation to taxation, please refer to “Appendix III — Taxation and Foreign Exchange.”

J. No Material Adverse Change

Save as disclosed in this prospectus, our Directors confirm that there has been no material adverse change in our financial or operational position since December 31, 2017.

K. Binding Effect

This prospectus shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

L. Related Party Transactions

Within the two years immediately preceding the date of this prospectus, we have entered into the related party transactions as described in Note 34 to the financial information in the Accountants’ Report set out in Appendix I.

M. Agency Fees or Commissions Paid or Payable

Save as disclosed in this prospectus, no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any capital of any member of our Group within the two years immediately preceding the date of this prospectus.

N. Miscellaneous

Save as disclosed in this prospectus,

- (a) within the two years immediately preceding the date of this prospectus, we have not issued nor agreed to issue any share or loan capital fully or partly paid either for cash or for a consideration other than cash;
- (b) no share or loan capital of our Group, if any, is under option or is agreed conditionally or unconditionally to be put under option;

- (c) we have not issued or agreed to issue any founder shares, management shares or deferred shares;
- (d) our Company has no outstanding convertible debt securities or debentures;
- (e) within the two years immediately preceding the date of this prospectus, no commission, discount, brokerage or other special term has been granted in connection with the issue or sale of any capital of our Company;
- (f) there is no arrangement under which future dividends are waived or agreed to be waived;
- (g) there has been no interruption in our business which may have or have had a significant effect on the financial position in the last 12 months;
- (h) none of the equity and debt securities of our Company, if any, is listed or dealt with in any other stock exchange nor is any listing or permission to deal being or proposed to be sought; and
- (i) we currently do not intend to apply for the status of a Sino-foreign investment joint stock limited company and do not expect to be subject to the Sino-foreign Joint Venture Law of the PRC.
- (j) within the two years immediately preceding the date of this prospectus, no commission has been paid or is payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription for any share in or debenture of our Company.

O. Bilingual Prospectus

The English language and Chinese language versions of this prospectus are being published separately in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

P. Preliminary Expenses

We have not incurred any preliminary expenses in connection with the Listing.